The breakthrough at Columbia University lays the groundwork for future clinical studies aimed at developing new treatments.

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...

As researchers in the laboratories and clinics of Fred Hutch Cancer Center strive to develop tomorrow’s cures for cancer, many are also pursuing innovative ways to improve the experience of people ...

Androgen receptor (AR) signaling plays a critical role in prostate cancer progression and remains a primary therapeutic ...

Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research ...

Beyond the physical, a prostate cancer diagnosis carries significant emotional weight. Understanding this spectrum of ...

Abstracts: 512 | 2517 | 3096 | 3145 | 4500 | 5005 | 5039 | 5083 | 5095 | 5103 | 6012 | 8618 | 8622 | 10036 | 11164 | e15604 | ...

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...

Maggie's, a national cancer charity, reported a 62% increase in attendance at its Scotland-based prostate cancer support ...

The ARASEC study prospectively examined darolutamide plus ADT in US men with mHSPC, but used a historical control group receiving ADT monotherapy from the phase 3 CHAARTED trial for matching and ...